<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490360</url>
  </required_header>
  <id_info>
    <org_study_id>21-2001</org_study_id>
    <nct_id>NCT00490360</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head</brief_title>
  <official_title>Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable&#xD;
      cancer of pancreatic head.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable&#xD;
      cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After&#xD;
      restaging excludes disease progression, a standard Whipple procedure is performed.&#xD;
&#xD;
      Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor&#xD;
      markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resectability rate &gt; 70% after restaging</measure>
    <time_frame>2007</time_frame>
  </primary_outcome>
  <enrollment type="Actual">2007</enrollment>
  <condition>Cancer of the Pancreatic Head</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine / Cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: - Age &gt; 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed resectable ductal adenocarcinoma of the&#xD;
             pancreatic head&#xD;
&#xD;
          -  WHO-performance status 0-2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Discussion in an intrdisciplinary conference&#xD;
&#xD;
        Exclusion criteria: - Insufficient renal function (calculated creatinin clearance &lt;&#xD;
        60ml(min)&#xD;
&#xD;
          -  Insufficient hematologic function (neutrophil count &lt;1'000/ul, platelets &lt; 100'000/ul)&#xD;
&#xD;
          -  Uncorrectable coagulopathy&#xD;
&#xD;
          -  Severe cholestasis (bilirubin &gt;100mmol/l)&#xD;
&#xD;
          -  Distant metastases in liver, lungs or other organs&#xD;
&#xD;
          -  Peritoneal carcinomatosis&#xD;
&#xD;
          -  Unresectable tumor (s. 4.2.)&#xD;
&#xD;
          -  Contraindication for Whipple procedure&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Neurotphil count &gt; Â°2&#xD;
&#xD;
          -  Estimated life experience &lt; 6 months&#xD;
&#xD;
          -  HIV Infection&#xD;
&#xD;
          -  Severe medical or psychatric comorbidities which interefere with the participation in&#xD;
             this trial or the informed consent&#xD;
&#xD;
          -  Female patients in child-bearing age without adequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Zurich, Department of Surgery</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

